摘要
肝细胞癌(hepatocellular carcinoma,HCC)是我国最常见的恶性肿瘤之一,发病率高,预后差,疾病进展迅速且隐匿性强,多数患者初诊时已为中晚期,严重威胁我国人民的生命健康。在免疫疗法兴起之前,放化疗、分子靶向药物为主要治疗方法。研究报道免疫检查点PD-1/PD-L1抑制剂或与其他方案联用,不仅能够促进机体正常免疫功能的恢复,还具有显著的抗肿瘤作用。本文总结了PD-1/PD-L1单药及联合抗血管生成剂、CTLA-4、分子靶向药物等其他新型方案在HCC治疗中可能的作用机制及研究现状,为HCC患者的临床免疫治疗提供参考。
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors in China.It is characterized by high morbidity,poor prognosis,rapid and insidious disease progression.Most patients are in the middle to late stages of HCC when they are first diagnosed,therefore,it poses a serious threat to people′s lives and health.Prior to the rise of immunotherapy,radiotherapy and molecularly targeted drugs were the main treatments.Studies have reported that immune checkpoint PD-1/PD-L1 inhibitors,or in combination with other regimens,not only promote the restoration of the body′s normal immune function,but also have significant anti-tumor effects.This article summarized the possible mechanisms of action and the current status of research on PD-1/PD-L1 alone and in combination with other novel regimens such as anti-angiogenic agents,CTLA-4,and molecularly targeted agents in the treatment of HCC for clinical immunotherapy of HCC.
作者
邵慧娟
李加佳
郑晓凤
马学锋
王炎
于晓辉
杨娇娥
张久聪
SHAO Huijuan;LI Jiajia;ZHENG Xiaofeng;MA Xuefeng;WANG Yan;YU Xiaohui;YANG Jiaoe;ZHANG Jiucong(Department of Gastroenterology,the 940 Hospital of Joint Logistic Support Force of PLA,Lanzhou 730050;The First Clinical Medical College,Gansu University of Traditional Chinese Medicine;Department of Gastroenterology,The Second Hospital of Lanzhou University;Department of Obstetrics and Gynecology,the 940 Hospital of Joint Logistic Support Force of PLA,China)
出处
《胃肠病学和肝病学杂志》
CAS
2023年第12期1426-1432,共7页
Chinese Journal of Gastroenterology and Hepatology
基金
甘肃省自然科学基金面上项目(21JR7RA002)
甘肃省自然科学基金青年项目(22JR5RA1012)
中央高校优秀青年团队培育项目(31920220065)
甘肃省非感染性肝病临床医学研究中心(21JR7RA017)。
